These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 25986581)

  • 1. Access to care for Chagas disease in the United States: a health systems analysis.
    Manne-Goehler J; Reich MR; Wirtz VJ
    Am J Trop Med Hyg; 2015 Jul; 93(1):108-13. PubMed ID: 25986581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Access to benznidazole for Chagas disease in the United States-Cautious optimism?
    Alpern JD; Lopez-Velez R; Stauffer WM
    PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005794. PubMed ID: 28910299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2001-2021.
    Abbott A; Montgomery SP; Chancey RJ
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(10):371-374. PubMed ID: 35271563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recognizing and meeting the challenge of Chagas disease in the USA.
    Bowling J; Walter EA
    Expert Rev Anti Infect Ther; 2009 Dec; 7(10):1223-34. PubMed ID: 19968514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to Chagas disease treatment in the United States after the regulatory approval of benznidazole.
    Yoshioka K; Manne-Goehler J; Maguire JH; Reich MR
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008398. PubMed ID: 32569280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies to enhance access to diagnosis and treatment for Chagas disease patients in Latin America.
    Alonso-Padilla J; Cortés-Serra N; Pinazo MJ; Bottazzi ME; Abril M; Barreira F; Sosa-Estani S; Hotez PJ; Gascón J
    Expert Rev Anti Infect Ther; 2019 Mar; 17(3):145-157. PubMed ID: 30712412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An overview of Chagas disease treatment.
    Jannin J; Villa L
    Mem Inst Oswaldo Cruz; 2007 Oct; 102 Suppl 1():95-7. PubMed ID: 17906803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How universal is coverage and access to diagnosis and treatment for Chagas disease in Colombia? A health systems analysis.
    Cucunubá ZM; Manne-Goehler JM; Díaz D; Nouvellet P; Bernal O; Marchiol A; Basáñez MG; Conteh L
    Soc Sci Med; 2017 Feb; 175():187-198. PubMed ID: 28107703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interventional study in the natural evolution of Chagas disease. Evaluation of specific antiparasitic treatment. Retrospective-prospective study of antiparasitic therapy].
    Gallerano RR; Sosa RR
    Rev Fac Cien Med Univ Nac Cordoba; 2000; 57(2):135-62. PubMed ID: 12934232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 12. Chagas disease. American trypanosomiasis.
    Kirchhoff LV
    Infect Dis Clin North Am; 1993 Sep; 7(3):487-502. PubMed ID: 8254156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chagas disease: clinical overview and implications for nursing.
    Lennox HA; Karcz DA; Tales H; El Masri M
    Medsurg Nurs; 2007 Aug; 16(4):229-35; quiz 236. PubMed ID: 17907695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of complement mediated lysis technic in patients with chronic Chagas' disease treated with trypanocidal drugs].
    Levy AM; Pereira VL; Boainain E
    Rev Inst Med Trop Sao Paulo; 1988; 30(1):32-9. PubMed ID: 3146793
    [No Abstract]   [Full Text] [Related]  

  • 15. Chagas disease: review of needs, neglect, and obstacles to treatment access in Latin America.
    Pinheiro E; Brum-Soares L; Reis R; Cubides JC
    Rev Soc Bras Med Trop; 2017; 50(3):296-300. PubMed ID: 28700045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 17. Short report: Increasing access to treatment for Chagas disease: the case of Morelos, Mexico.
    Manne-Goehler J; Ramsey JM; Salgado MO; Wirtz VJ; Reich MR
    Am J Trop Med Hyg; 2014 Dec; 91(6):1125-7. PubMed ID: 25266353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of the undetermined form of Chagas disease with nifortimox and benzonidazole].
    Ferreira Hde O
    Rev Soc Bras Med Trop; 1990; 23(4):209-11. PubMed ID: 2133586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanocarriers for effective delivery of benznidazole and nifurtimox in the treatment of chagas disease: A review.
    Arrúa EC; Seremeta KP; Bedogni GR; Okulik NB; Salomon CJ
    Acta Trop; 2019 Oct; 198():105080. PubMed ID: 31299283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chagas disease: the forgotten American neuroinfection.
    Lancet Neurology
    Lancet Neurol; 2009 Jun; 8(6):501. PubMed ID: 19446265
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.